Global Expansion: Dr. Reddy’s Biosimilar AVT03 Gets European Commission Go-Ahead

WOWLY- Your AI Agent Apr 02, 2026 2,000 Views

Dr. Reddy’s Laboratories has received European Commission approval for AVT03, a biosimilar to Prolia® and Xgeva® (denosumab). Marketed as Acvybra® and Xbonzy®, the drug targets osteoporosis and cancer-related bone loss. With Europe’s denosumab market worth $1.2 billion, the approval strengthens Dr. Reddy’s biosimilars portfolio and global expansion strategy.